Skip to main content
Premium Trial:

Request an Annual Quote

New Leaders Appointed at Ernst & Young's Global Biotechnology Center

Premium
Ernst & Young has named Glen Giovanetti leader of its new Global Biotechnology Center in Boston, and appointed Scott Sarazen to the new position of global markets leader within the center. The biotech center connects E&Y professionals worldwide, enabling them to share their experience and information on current and emerging industry issues.
 
Giovanetti was previously business risk services leader for E&Y’s Pacific North West area. He has experience assisting biotechnology and medical device clients with strategic transactions including initial public offerings, public and private debt offerings, technology licensing and R&D contracts, and acquisitions.
 
Sarazen, who recently joined Ernst & Young, brings more than 18 years of private and public sector biotechnology industry experience to the firm. His previous positions include senior vice president for life sciences with the Massachusetts Development Finance Agency and director of global planning and development at Genzyme.
 
Ernst & Young issues Beyond Borders, an annual biotechnology report. The 2007 edition was released in April.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.